# Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

> **NCT01386112** · PHASE1,PHASE2 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 24 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** EUR-1100
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01386112
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01386112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01386112, "Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01386112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*